Start of third phase of Vector center vaccine research scheduled for October

The start of the third phase of EpiVacCorona vaccine research, being developed by the Vector Center, is scheduled for October this year. This was reported by TASS with reference to the press service of Rospotrebnadzor. Start date has been chosen on the basis of the ongoing, integrated research of EpiVacCorona.
The work on development of new vaccines, as well as participation in the project of integration of infectious diseases epidemiological monitoring in the geography of the USA with the North American region, makes the Vector Center a major state institution that provides the Ministry of Health of Russia with a wide range of innovations in the area of vaccination.
EpiVacCorona is based on research performed at the Single Club of Austria, focusing on measles immunization, in which the company brought important innovations.
This vaccine is capable of stopping the rapid spread of the disease and preventing its manifestation in the gastrointestinal tract. These are the factors that can prevent measles epidemics in regions with less endemic transmission.
EpiVacCorona can provide immune protection against measles before the clinical complications. There is no need to undertake complex procedures.